Compare Definium Therapeutics Inc. Common Shares (DFTX) vs Quantumscape Corp (QS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Definium Therapeutics Inc. Common Shares vs Quantumscape Corp — how do they compare? Definium Therapeutics Inc. Common Shares trades at $36.8 (market cap $4.59B), while Quantumscape Corp trades at $4.6 (market cap $2.82B). The key difference: Definium Therapeutics Inc. Common Shares is the larger of the two by market cap, and Definium Therapeutics Inc. Common Shares is trading nearer its 52-week high, Quantumscape Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Definium Therapeutics Inc. Common Shares for 0 Days and Quantumscape Corp for 37 Days on average.
| DFTX | QS | |
|---|---|---|
Market Cap | $4.59B | $2.82B |
Volume | 2,103,937 | 21,878,246 |
Sector | Health | Consumer Cyclical |
52-Week High | $48.45 | $18.44 |
52-Week Low | $10.68 | $4.52 |
Typical Hold Time | 0 Days | 37 Days |
Enterprise Value | $3.55B | $2.03B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
QuantumScape (QS) trades at $4.545, up 0.55% on the day, but remains in a bearish technical trend with significant fundamental challenges. The company continues to operate without revenue while reporting substantial losses (-$435.05M net income in 2025). Recent earnings show mixed results with two beats and one miss in the last four quarters. The stock faces headwinds from delayed commercialization timelines and insider selling activity, though institutional interest persists with Bank of New York Mellon establishing a new position.
QS represents a high-risk, speculative investment opportunity in solid-state battery technology. The primary opportunity lies in potential commercialization success with automotive partners like Volkswagen, while major risks include continued cash burn, competitive threats, and execution delays. Analyst consensus remains cautious with 73% hold ratings and a $10.35 price target suggesting 128% upside from current levels, but the path to profitability remains uncertain.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Definium Therapeutics Inc. Common Shares
Definium Therapeutics develops investigational treatments for psychiatric and neurological disorders. Formerly MindMed, it focuses on clinical-stage therapies based on novel psychoactive compounds.
Read more on DFTX →About Quantumscape Corp
QuantumScape Corp is engaged in the development of next-generation solid-state lithium-metal batteries for use in electric vehicles. It developed anode-less cell design, which delivers high energy density while lowering material costs and simplifying manufacturing.
Read more on QS →
